Synonym
PSMA-BCH; NOTA-PSMA;
IUPAC/Chemical Name
L-Lysine, N6-[N-[[trans-4-[[[2-[4,7-bis(carboxymethyl)octahydro-1H-1,4,7-triazonin-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-3-(2-naphthalenyl)-L-alanyl]-N2-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]-
InChi Key
RNAPMUOYIJWPGN-FUFSVGPLSA-N
InChi Code
InChI=1S/C45H64N8O14/c54-37(26-51-17-19-52(27-39(57)58)21-22-53(20-18-51)28-40(59)60)47-25-29-8-12-32(13-9-29)41(61)48-36(24-30-10-11-31-5-1-2-6-33(31)23-30)42(62)46-16-4-3-7-34(43(63)64)49-45(67)50-35(44(65)66)14-15-38(55)56/h1-2,5-6,10-11,23,29,32,34-36H,3-4,7-9,12-22,24-28H2,(H,46,62)(H,47,54)(H,48,61)(H,55,56)(H,57,58)(H,59,60)(H,63,64)(H,65,66)(H2,49,50,67)/t29-,32-,34-,35-,36-/m0/s1
SMILES Code
O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
941.05
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Ren Y, Liu T, Liu C, Guo X, Wang F, Zhu H, Yang Z. An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2022 Apr 22;15(5):513. doi: 10.3390/ph15050513. PMID: 35631340; PMCID: PMC9143078.
2: Hu K, Li L, Huang Y, Ye S, Zhong J, Yan Q, Zhong Y, Fu L, Feng P, Li H. Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging. Pharmaceuticals (Basel). 2022 Mar 21;15(3):383. doi: 10.3390/ph15030383. PMID: 35337180; PMCID: PMC8949503.
3: Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, Jiang J, Xie Q, Yan K, Rowe SP, Zhu H, Yang Z. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4508-4516. doi: 10.1007/s00259-021-05426-9. Epub 2021 Jun 25. PMID: 34170361.
4: Liu T, Liu C, Xu X, Liu F, Guo X, Li N, Wang X, Yang J, Yang X, Zhu H, Yang Z. Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging. J Nucl Med. 2019 Sep;60(9):1284-1292. doi: 10.2967/jnumed.118.221671. Epub 2019 Feb 22. PMID: 30796170.
5: Liu T, Liu C, Liu F, Xu X, Guo X, Xia L, Zhu H, Yang Z. Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging. Bioorg Med Chem Lett. 2019 Apr 1;29(7):933-937. doi: 10.1016/j.bmcl.2019.01.013. Epub 2019 Jan 17. PMID: 30745258.
